WHY STRATYS
Gene therapy (GT) offers something fundamentally different from conventional pharmacology: the ability to intervene directly at the genetic source of disease. A therapeutic gene can restore a missing function, suppress a toxic one, or alter the underlying genetic program — creating the possibility of profound and potentially durable benefit from a single intervention.
That promise is no longer theoretical. Genetic medicines have transformed diseases once considered untreatable, and their therapeutic reach continues to expand across tissues, mechanisms and patient populations.12
Restore missing or defective function
Suppress a toxic gene product
Alter the underlying genetic program
As a recent illustration of expanding therapeutic reach: the FDA granted accelerated approval to the first gene therapy for OTOF-associated genetic hearing loss in April 2026, a dual-AAV therapy.3
The question is no longer whether genetic medicines can work. It is how broadly and safely we can make them work.
Act II
For a genetic payload to become a therapy, sufficient activity must reach the cells that matter, at a level capable of changing disease, while limiting unnecessary activity and exposure elsewhere.
This creates a fundamental efficacy–safety challenge. Too little productive activity may fail to alter disease; increasing vector exposure can improve target engagement but may also increase off-target exposure, immune burden and toxicity.4 These constraints become particularly important for systemic delivery and difficult-to-reach tissues such as the central nervous system.5
Sufficient productive activity in the cells that matter
Limit unnecessary exposure and activity elsewhere
High-dose AAV in particular has been associated with immune responses, hepatotoxicity, thrombotic microangiopathy and neurotoxicity.6
Act III
Delivery is fundamental to gene therapy and remains an important translational challenge. Accordingly, enormous scientific and engineering effort has been directed toward capsids, lipid nanoparticles, targeting technologies and other approaches designed to improve where genetic payloads go.7
But delivery is not the only determinant of therapeutic activity. Once a payload reaches a cell, its regulatory architecture determines whether it is expressed, in which cellular context, and at what level.
413 vs 20
Delivery-related vs. expression-control patent activity, 2025
~18×
More delivery-related than expression-control patent activity, 2021–2025
1.8%
Expression-control share of identified GT/editing patent activity
119
New U.S. in-vivo GT/editing clinical trials, 2021–2025
Methodology note: Patent categories were identified using title-based keyword classification and are non-exclusive.8 Counts are intended to illustrate relative technology-development trends, not provide a comprehensive patent landscape or freedom-to-operate analysis. Because relevant inventions may not explicitly reference these concepts in their titles, the absolute numbers should be considered conservative and may underestimate activity in each category. Clinical trial counts are based on the NIH Somatic Cell Genome Editing (SCGE) Gene Therapy Clinical Trials database.9
Why now
Our analysis identifies a large and established body of gene-therapy delivery IP, while expression-control activity remains comparatively small. Expression-control patent activity has been visible in every year of the analysis since first appearing in 2021 — it has not been ignored — but has held within a narrow band of roughly 20 to 23 events annually since 2022. Over the same five years, delivery-related patent activity grew from 283 to 413 events.
This is the profile of a category that has emerged from near-absence but has not yet scaled: present and sustained, but still small relative to the surrounding field.
413
Delivery IP events, 2025
The opportunity is not that expression control has been ignored. It is that the field appears to be early.
Stratys Tx is being built as this engineering layer begins to emerge.
Act IV
Which cells receive the payload?
Where, when and how much is it expressed?
Delivery and expression control are complementary engineering layers. Improving the therapeutic window may require optimizing both.
Stratys Tx is engineering the expression-control layer of genetic medicine.
Precision Control for Genetic Medicines
Patent landscape methodology and limitations. U.S. published patent applications and granted patents from 2021–2025 were classified using predefined title-based keyword sets for gene therapy/gene editing, delivery, and expression control. Categories are non-exclusive, such that a patent may contribute to more than one category when appropriate. This analysis is intended to evaluate broad technology-development trends and relative activity across categories; it is not a comprehensive patent landscape, claim-level analysis, or freedom-to-operate assessment.
The reported counts are likely conservative. Relevant inventions may use terminology not captured by the predefined keyword sets, may describe delivery or expression-control technologies primarily in abstracts, specifications or claims rather than titles, or may be classified under broader therapeutic terminology. Consequently, the analysis may underestimate the absolute level of patent activity in all categories. The comparison should therefore be interpreted primarily as a directional measure of relative engineering activity rather than an exhaustive count of intellectual property in each field.